These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9023649)

  • 61. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study.
    Jung BH; Choi MH; Chung BC
    Drug Dev Ind Pharm; 2000 Jan; 26(1):103-6. PubMed ID: 10677817
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Pharmacokinetics and bioavailability of clinafloxacin in rats].
    Zhou MH; Yu YQ; Duan GL; Cheng WB; Xu CJ; Liu X
    Yao Xue Xue Bao; 2001 Feb; 36(2):134-6. PubMed ID: 12579882
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats.
    Elmas M; Tras B; Kaya S; Bas AL; Yazar E; Yarsan E
    Can J Vet Res; 2001 Jan; 65(1):64-7. PubMed ID: 11227198
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tissue distribution and disposition kinetics of enrofloxacin in healthy and E. coli infected broilers.
    Soliman GA
    Dtsch Tierarztl Wochenschr; 2000 Jan; 107(1):23-7. PubMed ID: 10689795
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers.
    Mignot A; Guillaume M; Brault M; Gualano V; Millérioux L; Göhler K; Stahlberg HJ
    Chemotherapy; 2002 Jul; 48(3):116-21. PubMed ID: 12138326
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Comparative pharmacokinetics of lomefloxacin and other fluoroquinolones].
    Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):46-52. PubMed ID: 9825111
    [No Abstract]   [Full Text] [Related]  

  • 68. Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats.
    Kanemitsu K; Hori S; Yanagawa A; Shimada J
    Drugs; 1995; 49 Suppl 2():352-6. PubMed ID: 8549359
    [No Abstract]   [Full Text] [Related]  

  • 69. [Pharmacokinetics of balofloxacin in the intraocular tissues of pigmented rabbits].
    Ooishi M; Miyao M; Abe T; Sasagawa T; Motoyama M; Nakagawa T; Okutomi T
    Jpn J Antibiot; 1995 Sep; 48(9):1274-80. PubMed ID: 7474337
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetic study of danofloxacin in cattle and swine.
    Mann DD; Frame GM
    Am J Vet Res; 1992 Jun; 53(6):1022-6. PubMed ID: 1320812
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics and safety of lomefloxacin following multiple doses.
    Hunt TL; Adams MA
    Diagn Microbiol Infect Dis; 1989; 12(2):181-7. PubMed ID: 2752716
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.
    Naber CK; Steghafner M; Kinzig-Schippers M; Sauber C; Sörgel F; Stahlberg HJ; Naber KG
    Antimicrob Agents Chemother; 2001 Jan; 45(1):293-7. PubMed ID: 11120980
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical pharmacokinetics of sparfloxacin.
    Shimada J; Nogita T; Ishibashi Y
    Clin Pharmacokinet; 1993 Nov; 25(5):358-69. PubMed ID: 8287631
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics of the new fluoroquinolone balofloxacin in mice, rats, and dogs.
    Nakagawa T; Ishigai M; Kato M; Hayakawa N; Kinoshita H; Okutomi T; Ohkubo K; Okazaki A
    Arzneimittelforschung; 1995 Jun; 45(6):719-22. PubMed ID: 7646579
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of marbofloxacin in renal impairment in the dog.
    Lefebvre HP; Dupouy V; Schneider M; Laroute V; Toutain PL
    Vet Q; 1998; 20 Suppl 1():S104. PubMed ID: 9652038
    [No Abstract]   [Full Text] [Related]  

  • 77. Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers.
    Cook JA; Silverman MH; Schelling DJ; Nix DE; Schentag JJ; Brown RR; Stroshane RM
    Antimicrob Agents Chemother; 1990 Jun; 34(6):974-9. PubMed ID: 2393295
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Fillastre JP; Montay G; Bruno R; Etienne I; Dhib M; Vivier N; Le Roux Y; Guimart C; Gay G; Schott D
    Antimicrob Agents Chemother; 1994 Apr; 38(4):733-7. PubMed ID: 8031038
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of lomefloxacin in patients with cirrhosis.
    Lebrec D; Gaudin C; Benhamou JP
    Am J Med; 1992 Apr; 92(4A):41S-44S. PubMed ID: 1316069
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Biliary excretion of rufloxacin in humans.
    Privitera G; Nicastro G; Imbimbo BP; Cesana M; Visconti M; Lombardi F; Tagliabue G; Faleschini E; Colturani F; Franzini P
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2545-9. PubMed ID: 8109915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.